FibroBiologics, Inc. Common Stock (FBLG) Research

FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.

Market snapshot

Symbol
FBLG
Price
$0.77
Day change
-3.73%
Market cap
$1.6M
P/E ratio
-0.09x
52-week range
0.77-15.5
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 1 month
Analyst price target
$180

Recent news

  • EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial

    FibroBiologics Inc. (NASDAQ: FBLG) reports enrolling first patients in its Phase 1/2 trial for CYWC628, a fibroblast-based therapy targeting diabetic foot ulcers.

Peer companies

  • Aditxt, Inc. (ADTX)
  • Ainos, Inc. (AIMD)
  • Apollomics, Inc. (APLM)
  • Athira Pharma, Inc. (ATHA)
  • Citius Pharmaceuticals, Inc. (CTXR)
  • Daré Bioscience, Inc. (DARE)
  • Hoth Therapeutics, Inc. (HOTH)
  • SeaStar Medical Holding Corporation (ICU)

Recent insider activity

  • O'HEERON PETE — A-Award (92410 shares) on 2026-05-04
  • Khoja Hamid — A-Award (61607 shares) on 2026-05-04
  • Davis Jason — A-Award (61607 shares) on 2026-05-04
  • GARCIA RUBEN A — A-Award (61607 shares) on 2026-05-04
  • Khoja Hamid — P-Purchase (30000 shares) on 2026-03-04

Open FibroBiologics, Inc. Common Stock (FBLG) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.